Sentinel lymph node status provides important information about the status of the regional nodes in a variety of solid tumors, particularly breast cancer and melanoma. In order to minimize the extensive procedures and decrease morbidity in gynecologic malignancies, many studies were to investigate the feasibility of sentinel node evaluation. Now, the identification of sentinel nodes in vulvar and cervical cancers are reported to be feasible with preoperatively administered blue dye or radioactive tracers. Although this new technique of sentinel node mapping is safe and simple to perform, the rate of sentinel node identification is still low. In addition, many novel diagnostic methods such as immunohistochemistry staining and reverse transcriptase polymerase chain reaction assays are required to increase the accuracy of detection of disease. To incorporating sentinel node into the standard practice in vulvar and cervical carcinoma, further prospective randomized trials are warranted and they are believed to provide interesting and exciting information in this yielding field.